From USFDAZydus Cadila has received the final approval from the USFDA to market Tizanidine Tablets USP in the strengths of 2mg and 4mg. The drug is used to treat muscle spams caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)